|
| Author, year (country) | Type of study | Demographic details | Assessment of cognitive functions |
| Age (years) (mean ± SD) | Dose of atomoxetine (duration) | Concomitant medications | Comparator | Cognitive domain (DSM-5) | Scale and subscale used |
|
| Hinson et al. 2016 (USA) | Double-blind randomized control trial | 68 ± 8 | 40 mg/d (weeks 1-2); 80 mg/d (weeks 3–10); no dose adjustments | Memantine, anticholinergics, MAO inhibitors, neuroleptics, and acetylcholinesterase inhibitors excluded | Placebo | Complex attention | Paced Auditory Serial Addition Test |
| Complex attention | Neuropsychological Assessment Battery: Part A and Part D |
| Social cognition | Neuropsychological Assessment Battery: Judgement |
| Executive function | Delis–Kaplan Executive Function System—Inhibition Time |
| Executive function | Delis–Kaplan Executive Function System—Inhibition-Switching Time |
| Executive function | Delis–Kaplan Executive Function System—Number-Letter Switching Time |
| Executive function | Delis–Kaplan Executive Function System—Proverbs |
| Executive function | Wechsler Adult Intelligence Scale: Digit Span |
| Language | Expressive Language/Confrontation Naming |
| Perceptual-motor function | Visuospatial Perception |
| Complex attention | Conners’ Adult ADHD Rating Scale (Inattention) |
| Complex attention | Conners’ Adult ADHD Rating Scale (Hyperactivity) |
| Complex attention | Conners’ Adult ADHD Rating Scale (Impulsivity) |
| Complex attention | Conners’ Adult ADHD Rating Scale (Problems with self-concept) |
| Complex attention | Conners’ Adult ADHD Rating Scale (ADHD index) |
|
| Marsh et al. 2009 (USA) | Open-label single-arm trial | 57.3 ± 7.2 | 25 mg/d (week 1), 50 mg/d (weeks 2–4), 75 mg/d (week 5), 100 mg/d (weeks 6–8); minimum 2.5 mg/d dose reductions for intolerance | Dopamine agonists, levodopa, apomorphine, COMT inhibitors, anticholinergics, selegiline, amantadine, antidepressants, atypical antipsychotics, benzodiazepine/hypnotics allowed | Pretreatment vs. posttreatment | Learning and memory | Hopkins Verbal Learning Test-Revised Recognition Discrimination score |
| Complex attention | Conners’ Adult ADHD Rating Scale Long Form (Inattention/Memory) |
| Complex attention | Conners’ Adult ADHD Rating Scales Long Form (Hyperactivity) |
| Complex attention | Conners’ Adult ADHD Rating Scales Long Form (Impulsivity/Emotional Lability) |
| Complex attention | Conners’ Adult ADHD Rating Scales Long Form (Self-concept) |
| Complex attention | Conners’ Adult ADHD Rating Scales Long Form (Total ADHD Symptoms) |
|
| Weintraub et al. 2010 (USA) | Double-blind randomized control trial | 64.3 ± 10.5 | 40 mg/d (weeks 1-2), 80 mg/d (weeks 3–8); 40 mg/d allowed if indicated | Antidepressants allowed; MAO inhibitors excluded | Placebo | Global cognitive function | Mini-Mental State Examination |
|
